[go: up one dir, main page]

MX2018007815A - Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma. - Google Patents

Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma.

Info

Publication number
MX2018007815A
MX2018007815A MX2018007815A MX2018007815A MX2018007815A MX 2018007815 A MX2018007815 A MX 2018007815A MX 2018007815 A MX2018007815 A MX 2018007815A MX 2018007815 A MX2018007815 A MX 2018007815A MX 2018007815 A MX2018007815 A MX 2018007815A
Authority
MX
Mexico
Prior art keywords
tetrahidropyranil
pirrolopirimidinona
amino
methods
same
Prior art date
Application number
MX2018007815A
Other languages
English (en)
Other versions
MX384022B (es
Inventor
Lapierre Jean-Marc
Namdev Nivedita
Eathiraj Sudharshan
Nakayama Kiyoshi
Schwartz Brian
Ota Yusuke
Momose Takayuki
Tsunemi Tomoyuki
Inagaki Hiroaki
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MX2018007815A publication Critical patent/MX2018007815A/es
Publication of MX384022B publication Critical patent/MX384022B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (I): o una sal, tautómero, profármaco, solvato, metabolito, forma polimórfica, análogo, o derivado farmacéuticamente aceptable del mismo, que modula la actividad de la BTK, a una composición farmacéutica que comprende el compuesto de la fórmula (I), y a un método para el tratamiento o prevención de una enfermedad en la cual la BTK desempeña una función.
MX2018007815A 2015-12-23 2015-12-23 Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma. MX384022B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/000285 WO2017111787A1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2018007815A true MX2018007815A (es) 2019-07-04
MX384022B MX384022B (es) 2025-03-14

Family

ID=59090991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007815A MX384022B (es) 2015-12-23 2015-12-23 Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma.

Country Status (28)

Country Link
EP (2) EP3882250B1 (es)
JP (1) JP6634520B2 (es)
KR (2) KR102746900B1 (es)
CN (2) CN108699062B (es)
AU (3) AU2015417922B2 (es)
CA (1) CA3008446C (es)
CY (1) CY1124210T1 (es)
DK (2) DK3882250T3 (es)
ES (2) ES2942743T3 (es)
FI (1) FI3882250T3 (es)
HR (2) HRP20210844T1 (es)
HU (2) HUE055221T2 (es)
IL (2) IL259938B (es)
LT (2) LT3882250T (es)
MA (1) MA56553B1 (es)
MD (1) MD3882250T2 (es)
MX (1) MX384022B (es)
MY (1) MY193177A (es)
PH (1) PH12018501390B1 (es)
PL (2) PL3882250T3 (es)
PT (2) PT3394065T (es)
RS (2) RS61887B1 (es)
RU (1) RU2715421C2 (es)
SA (1) SA518391836B1 (es)
SG (1) SG11201805154YA (es)
SI (2) SI3394065T1 (es)
WO (1) WO2017111787A1 (es)
ZA (1) ZA201804091B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019108280A (ru) * 2016-08-24 2020-09-25 Аркьюл, Инк. Аминопирролопиримидиноновые соединения и способы их применения
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
WO2020239124A1 (en) * 2019-05-31 2020-12-03 Fochon Pharmaceuticals, Ltd. SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
CN117551103A (zh) * 2019-11-13 2024-02-13 浙江龙传生物医药科技有限公司 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
JP7011638B2 (ja) * 2019-12-16 2022-02-10 アークル インコーポレイテッド テトラヒドロピラニルアミノ-ピロロピリミジノンおよびその使用の方法
CN112608318B (zh) * 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途
KR20220123446A (ko) * 2020-01-02 2022-09-06 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Btk 억제제
KR20230110286A (ko) * 2020-11-17 2023-07-21 포천 바이오사이언시스, 리미티드 단백질 키나제 억제제로서 치환된 피롤로 [2,3-b] 피리딘 및 피라졸로 [3,4-b] 피리딘 유도체
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技(苏州)有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115028633B (zh) * 2021-03-08 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物的制备及其应用
WO2022213932A1 (zh) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
CN117794934A (zh) 2021-05-12 2024-03-29 浙江龙传生物医药科技有限公司 吡咯并嘧啶类化合物的晶型及其制备方法
CA3241069A1 (en) 2021-12-14 2023-06-22 Adrianus Petrus Antonius De Man Macrocyclic btk inhibitors
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715B (zh) * 2023-04-06 2025-04-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN102740698A (zh) * 2009-11-18 2012-10-17 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2014164729A1 (en) * 2013-03-12 2014-10-09 Arqule, Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
JP6495886B2 (ja) * 2013-03-15 2019-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としての複素環式芳香族化合物
GB201309085D0 (en) * 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds

Also Published As

Publication number Publication date
LT3394065T (lt) 2021-06-25
AU2020203690B2 (en) 2021-08-05
KR102746900B1 (ko) 2024-12-24
MA56553B1 (fr) 2023-04-28
PH12018501390A1 (en) 2019-02-27
KR20180096753A (ko) 2018-08-29
MA56553A (fr) 2022-04-27
RU2018126793A3 (es) 2020-01-23
EP3394065A1 (en) 2018-10-31
PL3394065T3 (pl) 2021-08-02
IL282572A (en) 2021-06-30
CY1124210T1 (el) 2022-05-27
ZA201804091B (en) 2019-03-27
SG11201805154YA (en) 2018-07-30
RS64141B1 (sr) 2023-05-31
RS61887B1 (sr) 2021-06-30
EP3882250B1 (en) 2023-02-15
WO2017111787A1 (en) 2017-06-29
BR112018012828A2 (pt) 2018-12-04
CN113307811A (zh) 2021-08-27
IL259938B (en) 2021-05-31
KR20230098690A (ko) 2023-07-04
CN113307811B (zh) 2023-11-14
DK3394065T3 (da) 2021-05-31
EP3394065A4 (en) 2019-07-10
PT3394065T (pt) 2021-05-06
PH12018501390B1 (en) 2022-06-10
FI3882250T3 (fi) 2023-04-27
LT3882250T (lt) 2023-05-25
CA3008446A1 (en) 2017-06-29
AU2020203690A1 (en) 2020-06-25
PL3882250T3 (pl) 2023-09-11
CN108699062A (zh) 2018-10-23
ES2868884T3 (es) 2021-10-22
IL282572B (en) 2022-04-01
SI3394065T1 (sl) 2021-08-31
JP2018538349A (ja) 2018-12-27
MX384022B (es) 2025-03-14
IL259938A (en) 2018-07-31
AU2019201737B2 (en) 2020-03-05
AU2015417922B2 (en) 2018-12-20
RU2018126793A (ru) 2020-01-23
MY193177A (en) 2022-09-26
EP3394065B1 (en) 2021-04-07
SA518391836B1 (ar) 2022-06-19
JP6634520B2 (ja) 2020-01-22
MD3882250T2 (ro) 2023-06-30
HUE055221T2 (hu) 2021-11-29
AU2019201737A1 (en) 2019-04-04
NZ743384A (en) 2024-05-31
RU2715421C2 (ru) 2020-02-28
CA3008446C (en) 2023-10-10
HRP20230379T1 (hr) 2023-06-23
PT3882250T (pt) 2023-04-21
DK3882250T3 (da) 2023-05-22
AU2015417922A1 (en) 2018-06-28
HUE061761T2 (hu) 2023-08-28
ES2942743T3 (es) 2023-06-06
SI3882250T1 (sl) 2023-07-31
HRP20210844T1 (hr) 2021-07-09
KR102547188B1 (ko) 2023-06-26
EP3882250A1 (en) 2021-09-22
CN108699062B (zh) 2021-06-29

Similar Documents

Publication Publication Date Title
MX2018007815A (es) Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma.
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
MX2016014253A (es) Inhibidores de desmetilasa-1 especifica de lisina.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
BR112016015236A8 (pt) composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença.
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
UY36124A (es) Derivados de carboxamida
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY36123A (es) Derivados de carboxamida
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
JP2017061576A5 (es)
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
EP3244930A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.